Cerebrolysin (Brain-Derived Peptide Preparation)
A pharmaceutical preparation of brain-derived peptides approved in 30+ countries for stroke, TBI, and dementia. The most clinically studied neuroprotective peptide treatment, with large-scale human trials. Administered by injection (IM or IV).
Cerebrolysin is essentially a cocktail of brain repair signals extracted from pig brain tissue. It contains fragments that mimic your brain's own growth and repair factors (BDNF, NGF, etc.), all delivered at once. This multi-signal approach protects neurons from dying, helps grow new ones, strengthens connections between existing ones, reduces brain inflammation, and may even help clear the protein tangles associated with Alzheimer's. Think of it as providing your brain with all the raw repair instructions it needs simultaneously.
The most clinically studied neuroprotective peptide treatment. RCTs in stroke (n=1070), Alzheimer's (n=279+), TBI. Approved in 30+ countries. Improves MMSE and ADAS-cog scores.
Specifically studied and used for brain injury recovery (stroke, TBI). Neuroprotective and neuroregenerative.
Promotes neuroplasticity and counters age-related neurodegeneration. Multiple mechanisms addressing brain aging.
Some clinical data showing mood improvement alongside cognitive benefits. Not a primary antidepressant.
Not primarily anxiolytic. Some indirect benefit through cognitive improvement.
May actually cause agitation/insomnia in some patients.
Anti-neuroinflammatory but not a systemic immune modulator.
Not relevant.
Not relevant.
Cerebrolysin contains neurotrophic peptide fragments that activate multiple neuroprotective and neuroplastic pathways simultaneously: (1) Neurotrophic effects mimicking BDNF, NGF, GDNF, and CNTF -- promoting neuronal survival, differentiation, and synaptic plasticity. (2) Neuroprotection against glutamate excitotoxicity via calpain inhibition. (3) Anti-apoptotic signaling preventing neuronal cell death. (4) Neurogenesis promotion in hippocampal dentate gyrus. (5) Reduction of amyloid-beta aggregation and tau hyperphosphorylation (Alzheimer's-relevant). (6) Anti-inflammatory effects reducing microglial activation. (7) Enhancement of synaptic remodeling and long-term potentiation. The multi-target nature (attacking multiple pathways simultaneously) is considered key to its efficacy.
The most practical at-home protocol. Requires IM injection (larger needle than subQ, 22-25 gauge, 1-1.5 inch). Inject slowly. Alternate injection sites. 5ml is a comfortable IM volume. Clinical protocols range from 5-30ml depending on indication.
Used in hospital/clinic settings for acute stroke and severe TBI. Not practical for home use. Higher doses than IM.
Protocol from Alzheimer's clinical trials. Showed improvement in cognitive and global function scores.
Neuroplasticity-related. Usually transient.
Porcine-derived product. Risk in patients with pork allergies.
Cerebrolysin has a well-documented safety profile from decades of clinical use and multiple RCTs. The CASTA trial (n=1,070) and Alzheimer's trials showed adverse event rates comparable to placebo. It is generally very well-tolerated. The main practical issue is the IM injection requirement.
Cerebrolysin is derived from porcine brain. Risk of allergic reaction.
Cerebrolysin may lower seizure threshold. Contraindicated in status epilepticus. Use with caution in controlled epilepsy.
Product labeling lists as contraindication. Peptide clearance may be affected.
No safety data in pregnancy.
Porcine brain-derived product. Manufacturing process includes steps to inactivate potential prion contamination, and no cases of prion transmission have been reported, but theoretical concern exists.
Contains peptide fragments mimicking BDNF activity. May increase endogenous BDNF expression.
Clinical trials showed statistically significant improvement in MMSE scores in Alzheimer's patients.
Improvement demonstrated in multiple clinical trials.
Preclinical data showing reduced amyloid aggregation.
May reduce pathological tau phosphorylation.
Marker of neuronal damage. Reduction indicates neuroprotective effect.
Studied together in Russian clinical literature. Different but complementary neurotrophic mechanisms. Cerebrolysin provides broad neuropeptide mix, Semax provides specific BDNF/melanocortin activation.
Complementary: Cerebrolysin for neuroregeneration, Selank for anxiolysis and GABA modulation.
No known interactions. Both have neuroprotective properties through different pathways.
Both promote neurotrophic/growth factor pathways. Combined growth factor stimulation has unknown safety profile. Conservative approach: use separately.
Heiss WD, Brainin M, Bornstein NM, et al. - J Stroke Cerebrovasc Dis (2012) - RCT (Phase 3, multicenter) - n=1070
30ml Cerebrolysin IV daily for 10 days in acute ischemic stroke. Although primary endpoint (ADAS-cog+ at 90 days) was not met, subgroup analyses showed significant benefits in patients with more severe strokes (NIHSS >12). Well-tolerated with safety profile comparable to placebo.
Limitations: Primary endpoint not met. Positive results only in subgroup analysis. Industry-funded.
Safarova ER, Shram SI, Grivennikov IA, Myasoedov NF - Bull Exp Biol Med (2002) - In vitro study
Both Cerebrolysin and Semax promote neuronal differentiation and survival in cell culture. Supports neurotrophic mechanism of action.
Limitations: In vitro data.
Alvarez XA, et al. - J Neural Transm (2006) - RCT - n=279
Cerebrolysin 30ml IV for 4 weeks showed significant improvement in ADAS-cog scores vs placebo in mild-to-moderate Alzheimer's disease. Benefits sustained at 3-month follow-up.
Limitations: Moderate sample size. Industry involvement.
Cerebrolysin is respected in the nootropic community as the 'real deal' for brain repair -- actual clinical trials, actual approval in real countries, actual decades of use. The main barriers are: (1) IM injection is more intimidating than nasal spray, (2) sourcing requires international pharmacies, (3) cost is higher than research peptides. Russian and Eastern European sources are most common (Cosmic Nootropic, pharmacy chains). Community advice: do a 10-day course of 5ml IM daily. Get ampoules, not vials. Draw up the full 5ml. Inject in upper outer quadrant of gluteal muscle or deltoid. 22-25 gauge needle. Inject slowly. Some users report feeling 'sharper' within the first course, with cumulative benefit over multiple courses. Most commonly used for: post-concussion syndrome, age-related cognitive decline, stroke recovery, and general cognitive enhancement. RELEVANT FOR OWEN: this is the most evidence-backed option for actual brain repair/regeneration. The IM injection is the main barrier vs the nasal ease of Semax/Selank.
NOT FDA-approved. Not available through US pharmacies. Can be obtained from international pharmacies (Eastern Europe, Russia, Asia). Some US peptide clinics import it. Not a controlled substance.
Cerebrolysin is manufactured by EVER Neuro Pharma (Austria) and is a registered pharmaceutical in 30+ countries including Russia, China, South Korea, and most of Eastern Europe. It is NOT FDA-approved and cannot be prescribed in the US. Patients typically obtain it from: (1) International pharmacies that ship to the US (legal gray area for personal use), (2) Travel to countries where it's OTC or prescribed, (3) Some US anti-aging clinics that import it. Personal importation for personal use is generally tolerated by FDA. Typical cost: $50-150 for a course of treatment from international pharmacies.
Tier 2. Multiple large RCTs in stroke (CASTA, n=1,070), Alzheimer's (n=819), and TBI. Approved in 50+ countries since 1954. Used clinically for decades. However, NOT FDA-approved in the United States. Cochrane reviews have noted methodological concerns in some trials. Best-studied neuroprotective peptide preparation globally, but lacks US regulatory approval.
Disclaimer: This information is for educational and research purposes only. PepStack does not provide medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare provider before using any peptide or supplement. Research suggests these compounds may have various effects, but individual results vary and many claims require further clinical validation.